XUANZHUBIO-B (02575) released its annual performance result, with a revenue of 51.772 million yuan, representing a year-on-year increase of 72.03%.

XUANZHUBIO-B (02575) released its annual performance for the year ending December 31, 2025. The group achieved revenue of 517.72 million RMB, an increase of 72.03% year-on-year; gross profit of 333.69 million RMB, an increase of 102.33% year-on-year; net loss attributable to owners of the parent company was 246 million RMB, a decrease of 55.88% year-on-year; loss per share was 0.53 RMB. During the reporting period, the group adopted flexible and targeted business strategies, maximizing the advantages of each listed product and target market, and achieving remarkable results. By the end of the reporting period, in the commercial layout of the digestive system drug Anjiuwei, the group adopted a distribution model combining provincial agents and refined investment promotion, established an internal sales team of 48 people, and built a sales network covering over 90 distributors and over 2,000 medical institutions nationwide; In the commercial promotion of the anti-tumor drugs Xuanyueling and Xuanfeining, the group implemented a direct sales strategy driven by both market and medical aspects, forming a professional commercial team of over 150 people, and orderly promoting the commercialization process of listed products domestically.